TopiVert (United Kingdom) a development-stage pharmaceutical company focused on topical medicines for inflammatory diseases of the eye and gut, closed a $12.5M Series A financing. Participants include Imperial Innovations Group and SV Life Sciences.

Affinium Pharmaceuticals (Austin, TX) a clinical-stage specialty pharmaceutical company focused on small molecule antibiotics targeting staph and MRSA infections, closed a $15M Series B financing. Participants include SV Life Sciences, Genesis Capital Partners, Forward Ventures and Ontario Emerging Technologies Fund.
Thanx for your patience as we catch-up.

Entellus Medical (Maple Grove, MN) a commercial-stage medical device company focused on minimally invasive treatments for chronic sinusitis, closed a $35M Series E financing. Participants include Covidien Ventures, SV Life Sciences, Essex Woodlands, Split Rock Partners and Greenspring Associates.
Thanx for your patience as we catch-up.

CardioKinetix (Redwood City, CA) a clinical-stage medical device company focused on transcatheter implants for congestive heart failure, closed a $44M Series E financing. Participants include SV Life Sciences, New Leaf Venture Partners, U.S. Venture Partners, J.P. Morgan Partners, H&Q Healthcare Investors and H&Q Life Sciences Investors.

Cyterix Pharmacautics (San Francisco, CA) a preclinical-stage small molecule pharmaceutical company focused on oncology,closed a $9.2M Series A financing. Participants include the Column Group and SV Life Sciences.

Delenex (Switzerland) a preclinical-stage biopharmaceutical company focused on CNS and dermatological diseases closed a $19.3M Series A financing, bringing the total round to $38.4M. Participants include Novo Ventures, SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners.

PanOptica (Mount Arlington, NJ) a development-stage biopharma company focused on in licensing IND-stage ophthalmology assets, closed a $30M Series A financing. Participants include SV Life Sciences and Third Rock Ventures.

Arsanis (Austria) a development stage biopharma focused on fully human monoclonal antibodies against severe infectious diseases, closed a $10M A financing. Participants include OrbiMed Advisors, Polaris Venture Partners and SV Life Sciences.

Sutro Biopharma (San Francisco, CA) a preclinical-stage biopharmaceutical company focused on partnering and developing proprietary protein therapeutics that have site directed modifications, closed a $36.5M Series C financing. Participants include Skyline Ventures, Lilly Ventures, Amgen Ventures, SV Life Sciences and Alta Partners.

Delenex Therapeutics (Switzerland) a clinical-stage biopharmacetucial company developing therapeutic antibody fragments targeting CNS and dermatological disease, closed a $14M Series A financing. Participants include SV Life Sciences, HBM BioCapital, BioMed Partners and VI Partners.

Convergence Pharmaceuticals (United Kingdom) a clinical-stage small molecule company focused on the treatment of neuropathic and chronic pain, closed a $35.4M Series A financing. Participants include New Leaf Venture Partners, Apposite Capital and SV Life Sciences.

Good Start Genetics (Boston, MA) a development-stage pre-pregnancy diagnostic company focused on a panel of genetic disorders including those recommended by the American Congress of Obstetricians and Gynecologists and the American College of Medical Genetics, closed a $18M Series A financing. Participants include OrbiMed Advisors, Safeguard Scientifics and SV Life Sciences.

AqueSys (Irvine, CA) a clinical-stage medical device company focused on implants for the treatment of glaucoma, closed a $25M Series C financing. Participants include Longitude Capital, Rho Ventures, Accuitive Medical Ventures, The Carlyle Group and SV Life Sciences.